Polymorphisms in genes involved in vasoactive eicosanoid synthesis affect cardiovascular risk in renal transplant recipients

References

• Bottomley MJ, Harden PN. Update on the long-term complications of renal transplantation. Br Med Bull 2013;106:117-34
   PubMed Web of Science ®Google Scholar
• Stoumpos S, Jardine AG, Mark PB. Cardiovascular morbidity and mortality after kidney transplantation. Transpl Int 2015;28:10-21
   PubMed Web of Science ®Google Scholar
• Wheeler DC, Steiger J. Evolution and etiology of cardiovascular diseases in renal transplant recipients. Transplantation 2000;70:SS41-5
   PubMed Web of Science ®Google Scholar
• Collins AJ, Foley RN, Chavers B, et al. US Renal Data System 2013 annual data report. Am J Kidney Dis 2014;63:A7
   PubMed Web of Science ®Google Scholar
• Jardine AG, Fellstrom B, Logan JO, et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) study. Am J Kidney Dis 2005;46:529-36
   PubMed Web of Science ®Google Scholar
• Marcen R. Cardiovascular risk factors in renal transplantation – current controversies. Nephrol Dial Transplant 2006;21(Suppl3):iii3-8
   Web of Science ®Google Scholar
• Gervasini G, Garcia M, Macias RM, et al. CYP2C8*3 polymorphism and donor age are associated with allograft dysfunction in kidney transplant recipients treated with calcineurin inhibitors. J Clin Pharmacol 2013;53:427-34
   PubMed Web of Science ®Google Scholar
• Gervasini G, Garcia-Cerrada M, Coto E, et al. A 3′-UTR polymorphism in soluble epoxide hydrolase gene is associated with acute rejection in renal transplant recipients. PLoS One 2015;10:e0133563
   PubMed Web of Science ®Google Scholar
• Gervasini G, Garcia-Cerrada M, Vergara E, et al. Polymorphisms in CYP-mediated arachidonic acid routes affect the outcome of renal transplantation. Eur J Clin Invest 2015;45:1060-8
   PubMed Web of Science ®Google Scholar
• Gervasini G, Luna E, Garcia-Cerrada M, et al. Risk factors for post-transplant diabetes mellitus in renal transplant: role of genetic variability in the CYP450-mediated arachidonic acid metabolism. Mol Cell Endocrinol 2016;419:158-64
   PubMed Web of Science ®Google Scholar
• Lee JP, Yang SH, Lee HY, et al. Soluble epoxide hydrolase activity determines the severity of ischemia-reperfusion injury in kidney. PLoS One 2012;7:e37075
   PubMed Web of Science ®Google Scholar
• Lee SH, Lee J, Cha R, et al. Genetic variations in soluble epoxide hydrolase and graft function in kidney transplantation. Transplant Proc 2008;40:1353-6
   PubMed Web of Science ®Google Scholar
• Yang L, Maki-Petaja K, Cheriyan J, et al. The role of epoxyeicosatrienoic acids in the cardiovascular system. Br J Clin Pharmacol 2015;80:28-44
   PubMed Web of Science ®Google Scholar
• Imig JD. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol 2005;289:F496-503
   PubMed Web of Science ®Google Scholar
• Theken KN, Schuck RN, Edin ML, et al. Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease. Atherosclerosis 2012;222:530-6
   PubMed Web of Science ®Google Scholar
• Seubert J, Yang B, Bradbury JA, et al. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K + channels and p42/p44 MAPK pathway. Circ Res 2004;95:506-14
   PubMed Web of Science ®Google Scholar
• Seubert JM, Sinal CJ, Graves J, et al. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res 2006;99:442-50
   PubMed Web of Science ®Google Scholar
• Wang X, Ni L, Yang L, et al. CYP2J2-derived epoxyeicosatrienoic acids suppress endoplasmic reticulum stress in heart failure. Mol Pharmacol 2014;85:105-15
   PubMed Web of Science ®Google Scholar
• Yu L, Shi D, Ma L, et al. Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos 2013;34:278-87
   PubMed Web of Science ®Google Scholar
• Bahadur N, Leathart JB, Mutch E, et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 2002;64:1579-89
   PubMed Web of Science ®Google Scholar
• Spiecker M, Liao J. Cytochrome P450 epoxygenase CYP2J2 and the risk of coronary artery disease. Trends Cardiovasc Med 2006;16:204-8
   PubMed Web of Science ®Google Scholar
• Dai D, Zeldin DC, Blaisdell JA, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001;11:597-607
   PubMedGoogle Scholar
• Spiecker M, Darius H, Hankeln T, et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 2004;110:2132-6
   PubMed Web of Science ®Google Scholar
• Liu PY, Li YH, Chao TH, et al Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction. Atherosclerosis. 2007;195:199-206
   PubMed Web of Science ®Google Scholar
• Donnelly MK, Conley YP, Crago EA, et al. Genetic markers in the EET metabolic pathway are associated with outcomes in patients with aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab 2015;35:267-76
   PubMed Web of Science ®Google Scholar
• Wang SY, Xing PF, Zhang CY, Deng BQ. Association of CYP2J2 gene polymorphisms with ischemic stroke and stroke subtypes in Chinese population. Medicine (Baltimore) 2017;96:e6266
   PubMed Web of Science ®Google Scholar
• Tzveova R, Naydenova G, Yaneva T, et al. Gender-specific effect of CYP2C8*3 on the risk of essential hypertension in Bulgarian patients. Biochem Genet 2015;53:319-33
   PubMed Web of Science ®Google Scholar
• Joosten SA, Sijpkens YW, van Kooten C, Paul LC. Chronic renal allograft rejection: pathophysiologic considerations. Kidney Int 2005;68:1-13
   PubMed Web of Science ®Google Scholar
• Perico N, Cattaneo D, Sayegh MH, Remuzzi G. Delayed graft function in kidney transplantation. Lancet 2004;364:1814-27
   PubMed Web of Science ®Google Scholar
• Levey AS, Greene T, Kuske J, et al. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000;11:155A
   Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-S266
   PubMed Web of Science ®Google Scholar
• Lebranchu Y, Baan C, Biancone L, et al. Pretransplant identification of acute rejection risk following kidney transplantation. Transpl Int 2014;27:129-38
   PubMed Web of Science ®Google Scholar
• Neale J, Smith AC. Cardiovascular risk factors following renal transplant. World J Transplant 2015;5:183-95
   PubMedGoogle Scholar
• Fedor R, Asztalos L, Locsey L, et al. Insertion/deletion polymorphism of the angiotensin-converting enzyme predicts left ventricular hypertrophy after renal transplantation. Transplant Proc 2011;43:1259-60
   PubMed Web of Science ®Google Scholar
• Melk A, Schildhorn C, Homme M, et al. Association of single nucleotide polymorphisms on chromosome 9p21.3 with cardiovascular death in kidney transplant recipients. Transplantation 2013;95:928-32
   PubMed Web of Science ®Google Scholar
• Kruger B, Banas MC, Walberer A, et al. A comprehensive genotype–phenotype interaction of different Toll-like receptor variations in a renal transplant cohort. Clin Sci (Lond) 2010;119:535-44
   PubMed Web of Science ®Google Scholar
• King LM, Ma J, Srettabunjong S, et al. Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol 2002;61:840-52
   PubMed Web of Science ®Google Scholar
• Murray M. CYP2J2 – regulation, function and polymorphism. Drug Metab Rev 2016;48:351-68
   PubMed Web of Science ®Google Scholar
• Zordoky BN, El-Kadi AO. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol Ther 2010;125:446-63
   PubMed Web of Science ®Google Scholar
• King LM, Gainer JV, David GL, et al. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenet Genomics 2005;15:7-13
   PubMedGoogle Scholar
• Polonikov AV, Ivanov VP, Solodilova MA, et al. A common polymorphism G-50T in cytochrome P450 2J2 gene is associated with increased risk of essential hypertension in a Russian population. Dis Markers 2008;24:119-26
   PubMed Web of Science ®Google Scholar
• Wu SN, Zhang Y, Gardner CO, et al. Evidence for association of polymorphisms in CYP2J2 and susceptibility to essential hypertension. Ann Hum Genet 2007;71:519-25
   PubMed Web of Science ®Google Scholar
• Lee CR, North KE, Bray MS, et al. CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study. Pharmacogenet Genomics 2007;17:349-58
   PubMed Web of Science ®Google Scholar
• Marciante KD, Totah RA, Heckbert SR, et al. Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic stroke. Pharmacogenet Genomics 2008;18:535-43
   PubMed Web of Science ®Google Scholar
• Arun Kumar AS, Kumar SS, Umamaheswaran G, et al. Association of CYP2C8, CYP2C9 and CYP2J2 gene polymorphisms with myocardial infarction in South Indian population. Pharmacol Rep 2015;67:97-101
   PubMed Web of Science ®Google Scholar
• Lundblad MS, Stark K, Eliasson E, et al. Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes. Biochem Biophys Res Commun 2005;327:1052-7
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Meineke I, Fuhr U, et al. Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids. Pharmacogenomics 2008;9:277-88
   PubMed Web of Science ®Google Scholar
• Yasar U, Bennet AM, Eliasson E, et al. Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics 2003;13:715-20
   PubMedGoogle Scholar
• Edin ML, Wang Z, Bradbury JA, et al. Endothelial expression of human cytochrome P450 epoxygenase CYP2C8 increases susceptibility to ischemia – reperfusion injury in isolated mouse heart. FASEB J 2011;25:3436-47
   PubMed Web of Science ®Google Scholar